ReviewNature aging2022
Designing the next-generation clinical care pathway for Alzheimer's disease.
Review in Nature aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Advancing Remote Monitoring for Patients With Alzheimer Disease and Related Dementias: Systematic Review.JMIR aging · 2025Pooled it
- Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes.The journal of prevention of Alzheimer's disease · 2026Trial
- Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Trial
- Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Trial
- Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025Trial
- Article
- Article
- Adapting the spanish healthcare system for disease-modifying treatments in early-stage alzheimer's disease.The journal of prevention of Alzheimer's disease · 2026Review
- Gut Microbiome Changes in Preclinical Alzheimer's Disease.Nutrients · 2026Review
- Druggable Pathophysiologic Targets in Alzheimer Disease: From Amyloid and Tau to Biomarker-Guided Multimodal Therapy.Dementia and neurocognitive disorders · 2026Review
- Microstate-Specific Cross-Frequency Coupling Networks: A Spatiotemporal Framework for MCI Identification.CNS neuroscience & therapeutics · 2026Article
- Clinical pathways matter for multimodal deep learning in early Alzheimer's disease detection.Scientific reports · 2026Article
- Clarifications and response to "Validating plasma biomarkers for distinguishing neurodegenerative and psychiatric disorders" by Boccardi et al.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Sex differences in the associations between illness representations and behavioral intentions to seek early Alzheimer's detection in Chinese older adults.BMC geriatrics · 2026Article
- Spatial navigation as a digital marker for clinically differentiating cognitive impairment severity.Communications medicine · 2026Article
- Predicting rates of cognitive and functional decline in Alzheimer's disease and mild cognitive impairment.Communications medicine · 2026Article
- The cGAS-STING pathway at the crossroads of neuroimmunology: bridging innate immunity to aging and neurodegeneration.Biomarker research · 2026Review
- Advancing Early Detection of Alzheimer Disease in the Primary Care Setting in the United States.Neurology. Clinical practice · 2026Article
- Tau in Alzheimer's disease: Shaping the future patient journey.The journal of prevention of Alzheimer's disease · 2026Review
- Precise Aβ clearance and antioxidant therapy in Alzheimer's disease via photoacoustic imaging-guided palladium hydride nanosheet-mediated photothermal treatment.BMC neuroscience · 2026Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
The reconceptualization of Alzheimer's disease (AD) as a clinical and biological construct has facilitated the development of biomarker-guided, pathway-based targeted therapies, many of which have reached late-stage development with the near-term potential to enter global clinical practice. These medical advances mark an unprecedented paradigm shift and requires an optimized global framework for clinical care pathways for AD. In this Perspective, we describe the blueprint for transitioning from the current, clinical symptom-focused and inherently late-stage diagnosis and management of AD to the next-generation pathway that incorporates biomarker-guided and digitally facilitated decision-making algorithms for risk stratification, early detection, timely diagnosis, and preventative or therapeutic interventions. We address critical and high-priority challenges, propose evidence-based strategic solutions, and emphasize that the perspectives of affected individuals and care partners need to be considered and integrated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.